X4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR) posted its quarterly earnings results on Wednesday. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.10, Zacks reports. The business had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.05 million. X4 Pharmaceuticals had a negative return on equity of 375.31% and a negative net margin of 311.15%.

X4 Pharmaceuticals Trading Down 1.1%

Shares of X4 Pharmaceuticals stock traded down $0.04 on Thursday, reaching $3.51. The company had a trading volume of 517,977 shares, compared to its average volume of 1,505,919. X4 Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $26.83. The company has a debt-to-equity ratio of 19.10, a quick ratio of 3.05 and a current ratio of 3.19. The firm’s 50 day moving average price is $3.42 and its two-hundred day moving average price is $3.06. The firm has a market cap of $40.04 million, a PE ratio of -0.24 and a beta of 0.51.

Insider Transactions at X4 Pharmaceuticals

In other news, Chairman Adam R. Craig purchased 86,206 shares of the firm’s stock in a transaction on Thursday, October 23rd. The shares were bought at an average cost of $2.90 per share, for a total transaction of $249,997.40. Following the completion of the purchase, the chairman directly owned 376,087 shares of the company’s stock, valued at approximately $1,090,652.30. This trade represents a 29.74% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.37% of the stock is currently owned by insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of institutional investors have recently modified their holdings of XFOR. Rhumbline Advisers grew its stake in shares of X4 Pharmaceuticals by 5.4% in the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after buying an additional 9,690 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after purchasing an additional 22,485 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of X4 Pharmaceuticals by 112.5% in the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after purchasing an additional 51,544 shares in the last quarter. 72.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on XFOR shares. Weiss Ratings restated a “sell (e+)” rating on shares of X4 Pharmaceuticals in a research report on Wednesday, October 8th. Zacks Research upgraded shares of X4 Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, October 21st. HC Wainwright set a $3.50 target price on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 13th. Finally, Stifel Nicolaus set a $7.50 target price on shares of X4 Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.67.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.